The Targeted technology Funds are focused on investing in life science companies that have the opportunity to advance ground breaking or disruptive technologies and which have the potential to significantly improve the outcomes for patients with significant medical conditions. We also favor technologies that can greatly impact the efficiency, cost or functionality of the development and manufacture of life science products. We believe that our life science investment model is particularly suited to today’s healthcare and economic environment that favors innovation which can improve clinical outcome and patient care and reduce healthcare budgets.